← Leaderboards
Abhimanyu Garg
Ut Southwestern Medical Center
$28,553,253
Attributed
$29,228,900
Total exposure
35
Grants
23
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$27,531,135 · 33
FDA$1,697,765 · 2
By mechanism
R01$22,140,690 · 9
M01$5,673,293 · 24
R33$864,288 · 1
R61$550,629 · 1
Top collaborators
- Mark S Anderson2 shared
Most similar at Ut Southwestern Medical Center
Same institution · by research overlap
- Joel M Goodman$3,983,780
- Zhao Zhang$3,642,127
Others in their field
Top investigators on “Lipodystrophy”
- Charles R Rinaldo · University Of Pittsburgh At Pittsburgh$50,848,965
- Steven M Wolinsky · Northwestern University$12,282,096
- Steven Kyle Grinspoon · Massachusetts General Hospital$12,198,952
- George M. Carman · Rutgers The St Univ Of Nj New Brunswick$11,203,140
- Karen Reue · University Of California Los Angeles$9,068,429
- Kenneth Alan Freedberg · Boston Medical Center$8,669,773
Research focus
LipodystrophyAdipose TissueClinical ResearchHuman SubjectDiabetes MellitusMetabolicInsulin ResistanceDyslipidemiasHypertriglyceridemiaMorbidity - Disease RateObesityFamilial Generalized LipodystrophyFatty LiverBody FatFamilial Partial LipodystrophyTriglyceridesResearch PersonnelAffectPhenotypeMagnetic Resonance ImagingSerumFatty Acid Glycerol EstersInsulin Sensitivity /ResistanceHuman Therapy Evaluation
Grant awards (92)
Genetic and Metabolic Basis of Familial Lipodystrophies$694,902
R01 · FY2025 · DK · contact PI
Autoimmune Basis of Acquired Lipodystrophies$677,951
R01 · FY2025 · DK · contact PI
Long term efficacy and safety of orlistat for type 1 hyperlipoproteinemia: a randomized, double-blind, placebo-controlled trial$436,509
R33 · FY2025 · HL · contact PI
Autoimmune Basis of Acquired Lipodystrophies$673,344
R01 · FY2024 · DK · contact PI
Genetic and Metabolic Basis of Familial Lipodystrophies$667,106
R01 · FY2024 · DK · contact PI
Long term efficacy and safety of orlistat for type 1 hyperlipoproteinemia: a randomized, double-blind, placebo-controlled trial$427,779
R33 · FY2024 · HL · contact PI
Genetic and Metabolic Basis of Familial Lipodystrophies$694,902
R01 · FY2023 · DK · contact PI
Long term efficacy and safety of orlistat for type 1 hyperlipoproteinemia: a randomized, double-blind, placebo-controlled trial$550,629
R61 · FY2023 · HL · contact PI
Genetic and Metabolic Basis of Familial Lipodystrophies$690,451
R01 · FY2021 · DK · contact PI
Genetic and Metabolic Basis of Familial Lipodystrophies$688,377
R01 · FY2020 · DK · contact PI
Genetic and Metabolic Basis of Familial Lipodystrophies$554,390
R01 · FY2018 · DK · contact PI
Genetic and Metabolic Basis of Familial Lipodystrophies$554,390
R01 · FY2017 · DK · contact PI
Phase 2 Study of Obeticholic Acid for Lipodystrophy Patients$364,500
R01 · FY2017 · DK · contact PI
Genetic and Metabolic Basis of Familial Lipodystrophies$560,975
R01 · FY2016 · DK · contact PI
Phase 2 Study of Orlistat and SLX-4090 for Type I Hyperlipoproteinemia$366,719
R01 · FY2016 · FD · contact PI
Phase 2 Study of Obeticholic Acid for Lipodystrophy Patients$363,656
R01 · FY2016 · DK · contact PI
Genetic and Metabolic Basis of Familial Lipodystrophies$560,704
R01 · FY2015 · DK · contact PI
Phase 2 Study of Obeticholic Acid for Lipodystrophy Patients$363,375
R01 · FY2015 · DK · contact PI
Phase 2 Study of Orlistat and SLX-4090 for Type I Hyperlipoproteinemia$397,162
R01 · FY2012 · FD · contact PI
Genetic and Metabolic Basis of Familial Lipodystrophies$582,962
R01 · FY2011 · DK · contact PI
Genetic and Metabolic Basis of Familial Lipodystrophies$73,966
R01 · FY2011 · DK · contact PI
Genetic and Metabolic Basis of Familial Lipodystrophies$590,898
R01 · FY2010 · DK · contact PI
Novel Therapies for Metabolic Complications in Patients with Lipodystrophies$317,481
R01 · FY2010 · DK · contact PI
Genetic and Metabolic Basis of Familial Lipodystrophies$90,500
R01 · FY2010 · DK · contact PI
Genetic and Metabolic Basis of Familial Lipodystrophies$581,096
R01 · FY2009 · DK · contact PI
Novel Therapies for Metabolic Complications in Patients with Lipodystrophies$320,688
R01 · FY2009 · DK · contact PI
Genetic and Metabolic Basis of Familial Lipodystrophies$565,758
R01 · FY2008 · DK · contact PI
Novel Therapies for Metabolic Complications in Patients with Lipodystrophies$320,688
R01 · FY2008 · DK · contact PI
Phase II study of cholic acid for hepatic steatosis in *$317,542
R01 · FY2008 · FD · contact PI
Genetic and Metabolic Basis of Familial Lipodystrophies$573,269
R01 · FY2007 · DK · contact PI
Novel Therapies for Metabolic Complications in Patients with Lipodystrophies$327,232
R01 · FY2007 · DK · contact PI
Phase II study of cholic acid for hepatic steatosis in *$311,234
R01 · FY2007 · FD · contact PI
MECHANISMS OF LIPODYSTROPHY IN HIV-INFECTED PATIENTS$48,308
M01 · FY2007 · RR · contact PI
LEPTIN TREATMENT IN HIV-1 PROTEASE INHIBITOR-INDUCED LIPODYSTROPHY$23,248
M01 · FY2007 · RR · contact PI
PHYSICAL AMP; METABOLIC ABNORMALITIES OF LIPODYSTROPHY$11,353
M01 · FY2007 · RR · contact PI
TREATMENT OF HYPERLIPIDEMIA OF HIV+ SUBJECTS$10,352
M01 · FY2007 · RR · contact PI
LEPTIN TREATMENT IN GENERALIZED LIPODYSTROPHY$8,939
M01 · FY2007 · RR · contact PI
THERAPEUTIC APPROACHES TO HAART-INDUCED LIPODYSTROPHY IN HIV PTS$7,992
M01 · FY2007 · RR · contact PI
NOVEL THERAPIES FOR METABOLIC COMPLICATION IN PATIENTS WITH LIPODYSTROPHIES$4,625
M01 · FY2007 · RR · contact PI
Genetic and Metabolic Basis of Familial Lipodystrophies$557,694
R01 · FY2006 · DK · contact PI
Therapeutic Approaches to HAART-Induced Lipodystrophy$380,835
R01 · FY2006 · DK · contact PI
MECHANISMS OF LIPODYSTROPHY IN HIV-INFECTED PATIENTS$354,222
M01 · FY2006 · RR · contact PI
Novel Therapies for Metabolic Complications in Patients with Lipodystrophies$351,255
R01 · FY2006 · DK · contact PI
Phase II study of cholic acid for hepatic steatosis in *$305,108
R01 · FY2006 · FD · contact PI
LEPTIN TREATMENT IN HIV-1 PROTEASE INHIBITOR-INDUCED LIPODYSTROPHY$81,681
M01 · FY2006 · RR · contact PI
PHYSICAL & METABOLIC ABNORMALITIES OF LIPODYSTROPHY$66,420
M01 · FY2006 · RR · contact PI
THERAPEUTIC APPROACHES TO HAART-INDUCED LIPODYSTROPHY IN HIV PTS$58,342
M01 · FY2006 · RR · contact PI
LEPTIN TREATMENT IN GENERALIZED LIPODYSTROPHY$47,232
M01 · FY2006 · RR · contact PI
TREATMENT OF HYPERLIPIDEMIA OF HIV+ SUBJECTS$1,668
M01 · FY2006 · RR · contact PI
Genetic and Metabolic Basis of Familial Lipodystrophies$556,416
R01 · FY2005 · DK
Therapeutic Approaches to HAART-Induced Lipodystrophy$390,000
R01 · FY2005 · DK
MECHANISMS OF LIPODYSTROPHY IN HIV-INFECTED PATIENTS$350,845
M01 · FY2005 · RR
LEPTIN TREATMENT IN GENERALIZED LIPODYSTROPHY$83,517
M01 · FY2005 · RR
PHYSICAL &METABOLIC ABNORMALITIES OF LIPODYSTROPHY$69,361
M01 · FY2005 · RR
THERAPEUTIC APPROACHES TO HAART-INDUCED LIPODYSTROPHY IN HIV PTS$60,738
M01 · FY2005 · RR
LEPTIN TREATMENT IN HIV-1 PROTEASE INHIBITOR-INDUCED LIPODYSTROPHY$54,346
M01 · FY2005 · RR
Genetic and Metabolic Basis of Familial Lipodystrophies$542,069
R01 · FY2004 · DK
Therapeutic Approaches to HAART-Induced Lipodystrophy$390,000
R01 · FY2004 · DK
Mechanisms of Lipodystrophy in HIV-infected Patients$217,367
M01 · FY2004 · RR
Physical &Metabolic Abnormalities of Lipodystrophy$91,028
M01 · FY2004 · RR
Leptin treatment in generalized lipodystrophy$81,062
M01 · FY2004 · RR
Treatment of Hyperlipidemia of HIV+ Subjects$33,561
M01 · FY2004 · RR
Leptin Treatment in HIV-1 Protease Inhibitor-Induced Lipodystrophy$28,397
M01 · FY2004 · RR
Therapeutic Approaches to HAART-Induced Lipodystrophy$22,201
M01 · FY2004 · RR
Genetic and Metabolic Basis of Familial Lipodystrophies$503,194
R01 · FY2003 · DK
Therapeutic Approaches to HAART-Induced Lipodystrophy$390,000
R01 · FY2003 · DK
MECHANISMS OF LIPODYSTROPHY IN HIV INFECTED PATIENTS$452,182
R01 · FY2002 · DK
GENETIC AND METABOLIC BASIS OF FAMILIAL LIPODYSTROPHIES$401,493
R01 · FY2002 · DK
Therapeutic Approaches to HAART-Induced Lipodystrophy$390,000
R01 · FY2002 · DK
PHYSICAL AND METABOLIC ABNORMALITIES OF LIPODYSTROPHY$321,374
M01 · FY2002 · RR
SKELETAL MUSCLE MORPHOLOGY AND EXERCISE RESPONSE IN LIPODYSTROPHY$321,374
M01 · FY2002 · RR
EFFECT OF DIETARY FIBER IN PATIENTS WITH NIDDM$321,374
M01 · FY2002 · RR
HIGH DOSE SIMVASTATIN IN HYPERTRIGLYCERIDEMIC NIDDM$321,374
M01 · FY2002 · RR
DIETARY SATURATED AND UNSATURATED FAT EFFECT IN NIDDM$321,374
M01 · FY2002 · RR
EFFECT OF HIGH FAT AND HIGH CARBOHYDRATE DIETS ON WEIGHT LOSS IN OBESE NIDDM$321,374
M01 · FY2002 · RR
MECHANISMS OF LIPODYSTROPHY IN HIV INFECTED PATIENTS$959,511
R01 · FY2001 · DK
MECHANISMS OF LIPODYSTROPHY IN HIV INFECTED PATIENTS$486,233
R01 · FY2001 · DK
GENETIC AND METABOLIC BASIS OF FAMILIAL LIPODYSTROPHIES$389,885
R01 · FY2001 · DK
SKELETAL MUSCLE MORPHOLOGY AND EXERCISE RESPONSE IN LIPODYSTROPHY$321,374
M01 · FY2001 · RR
HIGH DOSE SIMVASTATIN IN HYPERTRIGLYCERIDEMIC NIDDM$321,374
M01 · FY2001 · RR
DIETARY SATURATED AND UNSATURATED FAT EFFECT IN NIDDM$321,374
M01 · FY2001 · RR
EFFECT OF HIGH FAT AND HIGH CARBOHYDRATE DIETS ON WEIGHT LOSS IN OBESE NIDDM$321,374
M01 · FY2001 · RR
PHYSICAL AND METABOLIC ABNORMALITIES OF LIPODYSTROPHY$321,374
M01 · FY2001 · RR
EFFECT OF DIETARY FIBER IN PATIENTS WITH NIDDM$321,374
M01 · FY2001 · RR
MECHANISMS OF LIPODYSTROPHY IN HIV INFECTED PATIENTS$469,983
R01 · FY2000 · DK
GENETIC AND METABOLIC BASIS OF FAMILIAL LIPODYSTROPHIES$378,614
R01 · FY2000 · DK
EFFECT OF DIETARY FIBER IN PATIENTS WITH NIDDM$0
M01 · FY2000 · RR
HIGH DOSE SIMVASTATIN IN HYPERTRIGLYCERIDEMIC NIDDM$0
M01 · FY2000 · RR
DIETARY SATURATED AND UNSATURATED FAT EFFECT IN NIDDM$0
M01 · FY2000 · RR
EFFECT OF HIGH FAT &HIGH CARBOHYDRATE DIETS IN OBESE NIDDM$0
M01 · FY2000 · RR
PHYSICAL AND METABOLIC ABNORMALITIES OF LIPODYSTROPHY$0
M01 · FY2000 · RR
SKELETAL MUSCLE MORPHOLOGY &EXERCISE RESPONSE IN LIPODYSTROPHY$0
M01 · FY2000 · RR